Van Damme P, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9;
Della Cioppa G, et al. A dose-range study in older adults to compare the safety and immunogenicity profiles of MF59 adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccines Immunother 2014; 10:6, 1-10
Levin Y, Kochba E, Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: Are all delivery methods the same? Vaccine 2014; 34:4249-52;
Hung IF et al . Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 30 (2012) 2707– 2708
Hung IF, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35;
Levin Y. et al. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34 (2016) 5262–5272
Carter et al. The adjuvant GLA-AF enhances human intradermal vaccine responses. Sci. Adv. 2018; 4. eaas9930
Stephanie B. Troy et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis. (2015) 211 (12): 1969-1976
Anand A et al. Early priming with inactivated poliovirus vaccine (IPV) andintradermal fractional dose IPV administered by a microneedledevice: A randomized controlled trial. Vaccine 33 (2015) 6816–6822
10. Chan R Beals et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Aug;16(8):915-22
11. Hung IF et al. A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis. Clin Infect Dis. 2020 Jun 18;ciaa804. doi: 10.1093/cid/ciaa804. Online ahead of print.
Jacobse J et al. Comprehensive evaluation of microneedle-based intradermal adalimumab delivery versus subcutaneous administration: results of a randomized controlled trial. Br J Clin Pharmacol. 2021 Jan 5. doi: 10.1111/bcp.14729. Epub ahead of print. PMID: 33403697.
Nikolic T. et al. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide—for type 1 diabetes. Lancet Diabetes Endocrinol 2020, Published Online; May 5, 2020 https://doi.org/10.1016/S2213-8587(20)30104-2
Dul M. et al. Hydrodynamic gene delivery in human skin using a hollow microneedle device. J Control Release. 2017 Nov 10;265:120-131
Kouiavskaia D. et al. Intradermal Inactivated Poliovirus Vaccine: A Preclinical Dose-Finding Study. J Infect Dis. 2015 May 1;211(9):1447-50
Wang Y. et al. Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets. PLoS One. 2016 Nov 8;11(11)
Heine SJ. et al. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol. 2014 Feb 15;192(4):1630-40
Golombek S. et al. Intradermal Delivery of Synthetic mRNA Using Hollow Microneedles for Efficient and Rapid Production of Exogenous Proteins in Skin. Molecular Therapy Nucleic Acids Volume 11, 1 June 2018, Pages 382-392
Polomska AK. et al. Minimally invasive method for the point-of-care quantification of lymphatic vessel function. JCI Insight.2019 Feb 21;4(4)
Di Blasio S. et. al. The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. BioRxiv. 2019
Singh RK. et al. Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides. Nanomedicine: Nanotechnology, Biology.
The clinical results published herein were conducted to demonstrate clinical benefits and were not reviewed by any regulatory authorities.